文献速递临床试验与 GCP基础与转化研究

Mixodin补充剂对偏头痛患者炎症与氧化应激标志物、临床症状、心理健康及生活质量的影响:随机临床试验研究方案

Effect of mixodin supplementation on inflammatory and oxidative stress markers, clinical symptoms, mental health, and quality of life in patients with migraine: study protocol for a randomized clinical trial.
PubMed 文献 · Trials · 2025-10-23

本研究为随机双盲安慰剂对照试验方案,纳入60例依据ICHD-3标准诊断为偏头痛的患者,随机分入Mixodin组(n=30,每日两粒胶囊,每粒含姜黄素300 mg、姜辣素7.5 mg、胡椒碱3.75 mg,共8周)或安慰剂组(n=30)。主要结局为偏头痛发作频率、严重程度和持续时间,次要结局包括hs-CRP、CGRP、TAC、TOS、MDA、SOD、NO及心理健康与生活质量评估,旨在探讨Mixodin补充剂对上述指标的影响。

要点

  • Mixodin为含姜黄素、胡椒碱和姜辣素的天然生物活性复方制剂。
  • 纳入60例20至60岁经ICHD-3诊断的偏头痛患者,随机双盲安慰剂对照。
  • 干预组每日两粒胶囊,每粒含姜黄素300 mg、姜辣素7.5 mg、胡椒碱3.75 mg,共8周。

核心结论

  • 本试验旨在评估Mixodin补充剂对偏头痛患者炎症标志物、氧化应激、偏头痛相关症状、心理健康及生活质量的影响。
  • 结果可能为潜在机制提供见解,并支持制定纳入抗炎和抗氧化策略的循证临床指南以改善偏头痛治疗结局。

研究设计与样本

  • 随机、双盲、安慰剂对照临床试验方案,纳入60例由神经科医生依据ICHD-3标准诊断为偏头痛的患者。
  • 入选者年龄20至60岁,随机分为干预组(n=30)和对照组(n=30)。
  • 干预组每日服用两粒Mixodin胶囊,每粒含姜黄素300 mg、姜辣素7.5 mg、胡椒碱3.75 mg,持续8周;对照组每日服用两粒安慰剂胶囊,持续时间相同。

关键数值与推荐

  • 主要结局为患者报告的偏头痛临床症状,包括发作频率、严重程度和持续时间。
  • 次要结局包括血清高敏C反应蛋白(hs-CRP)、降钙素基因相关肽(CGRP)、总抗氧化能力(TAC)、总氧化状态(TOS)、丙二醛(MDA)、超氧化物歧化酶(SOD)、一氧化氮(NO)水平,以及心理健康状态和生活质量评估。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Migraine is a highly prevalent neurological disorder related to severe, unilateral headache and symptoms such as vomiting, nausea, and photophobia. Growing evidence implicates oxidative stress and inflammation as key contributors to migraine pathophysiology, exacerbating symptoms and related mental health conditions. Mixodin is a novel bioactive formulation derived from natural compounds, including curcumin, piperine, and gingerol, which are well-established for their anti-inflammatory and antioxidant properties. While each component has shown potential in alleviating migraine-related symptoms, the combined therapeutic efficacy remains unclear. This study investigates whether the combined natural compounds in mixodin provide synergistic benefits in migraine management by targeting multiple underlying mechanisms. This study aims to examine the effects of mixodin supplementation on clinical symptoms, mental health, quality of life (QOL), inflammatory, and oxidative stress factors in patients with migraine. METHODS: This study is a randomized, double-blind, placebo-controlled clinical trial involving 60 patients diagnosed with migraine by a neurologist according to the ICHD-3 criteria. Eligible participants, aged 20 to 60 years, will be randomly assigned to one of two groups. The intervention group (n = 30) will receive two mixodin capsules daily for 8 weeks, each containing 300 mg of curcumin, 7.5 mg of gingerol, and 3.75 mg of piperine. The control group (n = 30) will receive two placebo capsules daily for the same duration. The primary outcome will be the clinical symptoms of migraine, including the frequency, severity, and duration of migraine attacks reported by patients. Secondary outcomes will include serum levels of high-sensitivity C-reactive protein (hs-CRP), calcitonin gene-related peptide (CGRP), total antioxidant capacity (TAC), total oxidant status (TOS), malondialdehyde (MDA), superoxide dismutase (SOD), nitric oxide (NO), and assessments of mental health status and QOL. DISCUSSION: This clinical trial aims to evaluate the effects of mixodin supplementation on inflammatory markers, oxidative stress, migraine-related symptoms, mental health, and QOL in patients with migraine. The results may suggestion insights into underlying mechanisms and support the development of evidence-based clinical guidelines that incorporate anti-inflammatory and antioxidant strategies to enhance therapeutic outcomes in migraine management. TRIAL REGISTRATION: Iranian Registry of Clinical Trials ( www.irct.ir ) (ID: IRCT20241009063312N1). Registration date: 2024-12-15. TRIAL STATUS: The protocol is Version 2.0, March 01, 2025. Recruitment began November 11, 2024, and is anticipated to be completed by June 22, 2025.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Askari MA, Vajdi M, Khorvash F, et al. Effect of mixodin supplementation on inflammatory and oxidative stress markers, clinical symptoms, mental health, and quality of life in patients with migraine: study protocol for a randomized clinical trial. Trials. 2025. PMID: 41131591. doi:10.1186/s13063-025-09166-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。